Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALZT-OP1 in Early Alzheimer's Disease
NCT02547818Phase 3Completed
- Sponsor
- AZTherapies
- Start
- Sep 2015
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of sodium cromoglycate, ibuprofen in Alzheimer's disease (AD), sponsored by AZTherapies. Started Sep 2015; status: completed.
02
Drugs
sodium cromoglycateibuprofen
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02547818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02547818.